Pharvaris
Mary Burke Uhlenhopp has an extensive background in global advocacy, with experience in various leadership roles across different pharmaceutical companies such as Pharvaris, Takeda, Shire, and Baxalta (now part of Shire). Mary Burke has a strong background in patient advocacy, professional societies, and ally development across therapeutic areas. Mary also has experience as a clinical nurse specialist at Memorial Sloan-Kettering Cancer Center and as a head nurse at Northwestern University Hospital. Mary Burke holds a Master's in Public Health from Columbia University and a Master of Science in Nursing with a focus on Oncology from Columbia University Vagelos College of Physicians and Surgeons.
This person is not in the org chart
This person is not in any teams
Pharvaris
2 followers
Pharvaris is a preclinical stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients for use as an alternative to injected therapies for hereditary angioedema (HAE) and other B2 receptor-mediated indications. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.